Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants

被引：18

作者：

Kawade, Anand ^{[1
]}

Babji, Sudhir ^{[1
,2
]}

Kamath, Veena ^{[3
]}

Raut, Abhishek ^{[4
]}

Kumar, Chandra Mohan ^{[5
]}

Kundu, Ritabrata ^{[6
]}

Venkatramanan, Padmasani ^{[7
]}

Lalwani, Sanjay K. ^{[8
]}

Bavdekar, Ashish ^{[1
]}

Juvekar, Sanjay ^{[1
]}

Dayma, Girish ^{[1
]}

Patil, Rakesh ^{[1
]}

Kulkarni, Muralidhar ^{[3
]}

Hegde, Asha ^{[3
]}

Nayak, Dinesh ^{[3
]}

Garg, B. S. ^{[4
]}

Gupta, Subodh ^{[4
]}

Jategaonkar, Smita ^{[4
]}

Bedi, Nidhi ^{[5
]}

Maliye, Chetna ^{[4
]}

Ganguly, Nupur ^{[6
]}

Uttam, Kheya Ghosh ^{[6
]}

Niyogi, Prabal ^{[6
]}

Palkar, Sonali ^{[8
]}

Hanumante, Neeta ^{[8
]}

Goyal, Nidhi ^{[9
]}

Arya, Alok ^{[9
]}

Aslam, Mohd. ^{[9
]}

Paruiekar, Varsha ^{[10
]}

Dharmadhikari, Abhijeet ^{[11
]}

Gaikwad, Dutta ^{[11
]}

Zade, Jagdish ^{[11
]}

Desai, Sajjad ^{[11
]}

Kang, Gagandeep ^{[2
]}

Kulkarni, Prasad S. ^{[11
]}

机构：

[1] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India

[2] Christian Med Coll Vellore, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India

[3] Manipal Acad Higher Educ, Manipal, Karnataka, India

[4] Mahatma Gandhi Inst Med Sci, Sevagram, India

[5] Hamdard Inst Med Sci & Res, Delhi, India

[6] Inst Child Hlth Kolkata, Kolkata, India

[7] Sri Ramachandra Med Ctr, Chennai, Tamil Nadu, India

[8] Bharati Vidyapeeth Med Coll & Hosp, Pune, Maharashtra, India

[9] Soc Appl Studies, Ctr Hlth Res & Dev, Delhi, India

[10] DiagnoSearch Life Sci Pvt Ltd, Mumbai, Maharashtra, India

[11] Serum Inst India Pvt Ltd, 212-2 Hadapsar, Pune, Maharashtra, India

来源：

VACCINE | 2019年 / 37卷 / 19期

关键词：

Liquid Bovine-Human Reassortant; Pentavalent Rotavirus Vaccine (LBRV-PV); Lot-to-lot consistency; Immunogenicity; Safety; SAFETY; IMPACT; MORTALITY; EFFICACY; CHILDREN; TRIAL; COST;

D O I：

10.1016/j.vaccine.2019.03.067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: A lyophilized bovine-human rotavirus reassortant pentavalent vaccine (BRV-PV, Rotasiil (R)) was licensed in 2016. A liquid formulation of this vaccine (LBRV-PV, Rotasiil - Liquid) was subsequently developed and was tested for non-inferiority to Rotasiil (R) and for lot-to-lot consistency. Methods: This Phase open II/III, randomized study was conducted at seven sites across India from November 2017 to June 2018. Participants were randomized into four arms; Lots A, B, and C of LBRV-PV and Rotasiil (R) in 1:1:1:1 ratio. Three doses of study vaccines were given at 6, 10, and 14 weeks of age. Blood samples were collected four weeks after the third dose to assess rotavirus IgA antibody levels. Non-inferiority of LBRV-PV to Rotasiil was proven if the lower limit two-sided 95% confidence interval (CI) of geometric mean concentration (GMC) ratio was at least 0.5. Lot-to-lot consistency was proven if 95% CI of the GMC ratios of three lots were between 0.5 and 2. Solicited reactions were collected by using diary cards. Results: Of the 1500 randomized infants, 1436 infants completed the study. The IgA GMC ratio of LBRV-PV to Rotasiil (R) was 1.19 (95% CI 0.96, 1.48). The corresponding IgA seropositivity rates were 60.41% (57.41, 63.35) and 52.75% (47.48, 57.97). The IgA GMC ratios among the three LBRV-PV lots were: Lot A versus Lot B: 1.34 (1.03, 1.75); Lot A versus Lot C: 1.22 (0.93, 1.60); and Lot B versus Lot C: 0.91 (0.69, 1.19). The 95% Cls for the GMC ratios were between 0.69 and 1.75. The incidence of solicited reactions was comparable across the four arms. Only one serious adverse event of gastroenteritis event in the Rotasiil (R) group was causally related. Conclusion: The immunological non-inferiority of LBRV-PV against Rotasiil as well as lot-to-lot consistency of LBRV-PV was demonstrated. LBRV-PV had safety profile similar to Rotasiil (R). (C) 2019 Elsevier Ltd. All rights reserved.

引用

页码：2554 / 2560

页数：7

共 45 条

[1] A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
Rathi, Niraj
Desai, Sajjad
Kawade, Anand
Venkatramanan, Padmasani
Kundu, Ritabrata
Lalwani, Sanjay K.
Dubey, A. P.
Rao, J. Venkateswara
Narayanappa, D.
Ghildiyal, Radha
Gogtay, Nithya
Venugopal, P.
Palkar, Sonali
Munshi, Renuka
Kang, Gagandeep
Babji, Sudhir
Bavdekar, Ashish
Juvekar, Sanjay
Ganguly, Nupur
Niyogi, Prabal
Uttam, Kheya Ghosh
Rajani, H. S.
Kondekar, Alpana
Kumbhar, Dipti
Mohanlal, Smilu
Agarwal, Mukesh C.
Shetty, Parvan
Antony, Kalpana
Gunale, Bhagwat
Dharmadhikari, Abhijeet
Tang, Yuxiao
Kulkarni, Prasad S.
Flores, Jorge
VACCINE, 2018, 36 (52) : 7943 - 7949
[2] Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
Gillard, P.
Benninghoff, B.
VACCINE, 2019, 37 (23) : 2990 - 2990
[3] Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
Desai, Sajjad
Rathi, Niraj
Kawad, Anand
Venkatramanan, Padmasani
Kundu, Ritabrata
Laiwani, Sanjay K.
Dubey, A. P.
Rao, J. Venkateswara
Narayanappa, D.
Ghildiyal, Radha
Gogtay, Nithya J.
Venugopal, P.
Palkar, Sonali
Munshi, Renuka
Bavdekar, Ashish
Juvekar, Sanjay
Ganguly, Nupur
Niyogi, Prabal
Uttam, Kheya Ghosh
Kondekar, Alpana
Kumbhar, Dipti
Mohanlal, Smilu
Agarwal, Mukesh C.
Shetty, Parvan
Antony, Kalpana
Gunale, Bhagwat
Dharmadhikari, Abhijeet
Deshpande, Jagdish
Nalavade, Uma
Sharma, Deepa
Bansal, Anurag
Tang, Yuxiao
Flores, Jorge
Kulkarni, Prasad S.
VACCINE, 2018, 36 (37) : 5519 - 5523
[4] RotaTeq: A pentavalent bovine-human reassortant rotavirus vaccine
Offit, PA
Clark, HF
PEDIATRIC ANNALS, 2006, 35 (01): : 29 - 34
[5] EVALUATION OF A BOVINE-HUMAN ROTAVIRUS REASSORTANT VACCINE IN INFANTS
CHRISTY, C
OFFIT, P
CLARK, HF
TREANOR, J
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1598 - 1599
[6] Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants
Gandhi, Dulari J.
Dhaded, Sangappa M.
Ravi, Mandyam D.
Dubey, Anand P.
Kundu, Ritabrata
Lalwani, Sanjay K.
Chhatwal, Jugesh
Mathew, Leni G.
Gupta, Madhu
Sharma, Shiv D.
Bavdekar, Sandeep B.
Jayanth, Midde V.
Ravinuthala, Suresh
Sil, Arijit
Dhingra, Mandeep S.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (04) : 946 - 954
[7] Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants
Block, Stanley L.
Klein, Nicola P.
Sarpong, Kwabena
Russell, Stephen
Fling, John
Petrecz, Maria
Flores, Sheryl
Xu, Jin
Liu, Guanghan
Stek, Jon E.
Foglia, Ginamarie
Lee, Andrew W.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (02) : 202 - 208
[8] A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants
Kulkarni, Prasad S.
Desai, Sajjad
Tewari, Tushar
Kawade, Anand
Goyal, Nidhi
Garg, Bishan Swarup
Kumar, Dinesh
Kanungo, Suman
Kamat, Veena
Kang, Gagandeep
Bavdekar, Ashish
Babji, Sudhir
Juvekar, Sanjay
Manna, Byomkesh
Dutta, Shanta
Angurana, Rama
Dewan, Deepika
Dharmadhikari, Abhijeet
Zade, Jagdish K.
Dhere, Rajeev M.
Fix, Alan
Power, Maureen
Uprety, Vidyasagar
Parulekar, Varsha
Cho, Iksung
Chandola, Temsunaro R.
Kedia, Vikash K.
Raut, Abhishek
Flores, Jorge
VACCINE, 2017, 35 (45) : 6228 - 6237
[9] Immunogenicity and safety of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine (PRV) in Indian infants
Lokeshwar, M. R.
Bhave, Sheila
Gupta, Ashok
Goyal, V. K.
Walia, Anuj
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (01) : 172 - 176
[10] Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem® demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine
Aspinall, Sanet
Traynor, Deirdre
Bedford, Philip
Hartmann, Katharina
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1109 - 1118

← 1 2 3 4 5 →